Based on the results of recent RCTs, the application of immunotherapy in GC has been limited to unresectable or metastatic disease harboring specific immunotherapy-responsive molecular phenotypes, e.g., PD-L1 positive, MSI-H, and TMB-H [7,24,25]. This evidence concerns the gene CD274 and gastric cancer.